• Laura Groneck, Alexander Quaas, Michael Hallek, Thomas Zander, and Martin R Weihrauch.
• Klinik I für Innere Medizin, Hämatologie und Onkologie, Universitätsklinik Köln, Köln, Germany. laura.groneck@uk-koeln.de.
• Eur. J. Haematol. 2016 Oct 1; 97 (4): 379-86.

BackgroundFor the histopathological diagnosis of lymphoma, lymph node excision biopsies are regarded as standard of care. In contrast, for the diagnosis of carcinoma and deep-seated tumors, core needle biopsies (CNBs) are accepted as a sufficient sampling method. We evaluated a diagnostic algorithm for peripheral lymphadenopathy starting with ultrasound-guided CNB followed by excisional biopsy in ambiguous cases.MethodsWe performed ultrasound-guided CNB of peripheral lymph nodes and subcutaneous tumors in patients with lymphadenopathy in routine care and analyzed its accuracy, complication rate, and the impact of needle sizes on results.ResultsFrom 138 patients, 132 samples were technically adequate. In 121 patients, CNB provided a clinically actionable diagnosis (76 lymphoma, 30 carcinoma, 15 non-malignant diagnoses). A total of 54 patients had a secondary biopsy. Inconclusive diagnoses were rare with two false-positive and two false-negative non-Hodgkin's lymphoma, and higher for Hodgkin's lymphoma with five false-negative cases. The rate of complications was low. Needle size did not significantly influence results.ConclusionUltrasound-guided CNBs are a safe, quick, and valid tool for the workup of lymphadenopathy. Yet, a benign diagnosis from CNB must be completed by a secondary biopsy if clinical presentation suggests malignant disease.© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

24 keywords...

hide…